Mentor Capital Cancer Immunotherapy Index Gains 31% During First Half of 2013

Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer
Immunotherapy Index appreciated 30.6% during the first half of 2013. The
equally weighted Cancer Immunotherapy Index is regularly benchmarked against
the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices.
For the first half the biotech indices
averaged a 34.5% gain.

Galena (45%), Inovio (59%) and Celldex (133%) have led the sector in gains
during the January thru June 2013 period. Dendreon ($650 Million), Celldex
($1,262 Million) and NewLink Genetics ($392 Million) represent 66% of the
market capitalization of the fifteen member Cancer Immunotherapy Index which
has a combined total share value of $3.5 Billion.

The Mentor Capital Cancer Immunotherapy Index companies and their
performance for the first twenty-six weeks of 2013 follow: Galena Biopharma
Corporation (NASDAQ:GALE) +45.10%, NewLink Genetics Corporation (NASDAQ:NLNK) +22.40%, Vical Incorporated (NASDAQ:VICL) +7.56%,
Inovio Pharmaceuticals, Inc. (NYSEMKT:INO) +59.36%, Dendreon (NASDAQ:DNDN) -22.12%, Immunocellular
Therapeutics, Ltd. (NYSE MKT:IMUC) +1.04%, Agenus (NASDAQ:AGEN) -7.56%, Oncothyreon (NASDAQ:ONTY) -18.23%, Biovest
International (OTCMKTS:BVTIQ) -84.80%, Celldex Therapeutics (NASDAQ:CLDX)
+132.64%, Northwest Biotherapeutics (NASDAQ:NWBO) +7.07%, CEL ? SCI Corp. (NYSEMKT:CVM)
-21.11% , Generex Biotechnology (OTCBB:GNBT) +32.00% as a proxy for its
wholly-owned immunotherapeutic subsidiary, Antigen Express, Provectus
Pharmaceuticals, Inc. (OTCMKTS:PVCT) +14.29% and Advaxis, Inc. (OTCBB:ADXSD)
+34.67% - all for an average 2013 YTD gain of +30.60%. (Annualized rate: +61.20%).

Mentor Capital, Inc., by acquisition or stock purchase,
seeks to invest in leading-edge private and public cancer companies, and
certain other situations. Mentor created the Cancer Immunotherapy Index July
10, 2009. Since then, it has invested or
maintained a tracking position in all companies in the Cancer Immunotherapy
Index which can be found at www.MentorCapital.com.

Forward Looking Statements, Safe Harbor and Risk Descriptions
are Incorporated by Reference from the MNTR Company Web Site above.

For further information contact:

Chester Billingsley, CEO

Mentor Capital, Inc.

Mentor Capital (QB) (USOTC:MNTR)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024